Monsenso and a consortium of partners have received a grant letter from a funding entity to develop and trial a new, AI-enabled personalised therapy concept for people with mental disorders.
Currently, digital mental health interventions are largely developed as a one-size-fits-all approach, where patients get a fixed 6-12 week intervention and where drop-out rates are relatively high.
With the grant letter received, Monsenso is entering grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, health economics and AI to develop and trial a new AI-enabled personalised care concept based on Monsenso’s platform. The four-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 3.9 mio to Monsenso.
“With this project, we will further develop our platform’s ability to deliver personalised digital treatment programs and to ensure optimal adherence to treatment. By leveraging patients’ own data and artificial intelligence, the aim is to be able to give more engaging and personalised care based on patients’ actual state, so that patients are offered the right treatment at the right time in a scalable way”, says Thomas Lethenborg, CEO of Monsenso.
Full disclosure of the project details including consortium members, funding program, and disorder area will be possible upon signature of the grant agreement, which is expected in Q1 of 2023.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit www.monsenso.com.